MR001

MR001 is a bispecific antibody currently in Phase 1 clinical trials for advanced solid tumors. It targets CD4 and TGF-β1, making it a potential immunotherapy agent for cancer treatment. ## Drug Profile MR001 was initially developed by Shenzhen Maijiarui Biotechnology Co., Ltd. and is currently being evaluated in first-in-human studies for patients with advanced solid tumors, including pancreatic cancer and triple-negative breast cancer[1][2]. The clinical trial (NCT06134531) is designed to assess the safety, tolerability, and preliminary efficacy of this bispecific antibody[2]. ## Mechanism of Action As an anti-CD4/anti-TGFβ1 bispecific antibody, MR001 appears to target two important pathways in cancer immunology[2]. CD4 is a glycoprotein found on the surface of immune cells, while TGF-β1 (Transforming Growth Factor beta 1) is a cytokine that can promote tumor growth and suppress immune responses in the tumor microenvironment. ## Clinical Development The Phase 1 trial for MR001 follows a dose-escalation design with multiple dose levels ranging from 0.5 mg/kg to 20 mg/kg administered intravenously every 3 weeks[2]. The study consists of two parts: 1. Dose escalation to determine the maximum tolerated dose 2. Expansion at the recommended Phase 2 dose The trial began in late 2023, with the most recent start date being December 28, 2023[1][2]. It is being conducted in China and is currently listed as "not yet recruiting" as of the available information[2]. ## Target Indications MR001 is being investigated for: - Advanced malignant solid neoplasms - Pancreatic cancer - Triple-negative breast cancer[1] This bispecific antibody represents an emerging approach in cancer immunotherapy, potentially offering a new treatment option for patients with difficult-to-treat solid tumors.